MOTS-C Dosage Chart: How to Actually Protocol This Mitochondrial Peptide

The Mitochondrial Peptide Everyone's Talking About (and Almost No One Is Dosing Correctly)

Spend enough time in longevity circles and you'll hear about MOTS-c. It pops up in the same breath as NAD precursors and rapamycin — a molecule that seems almost too convenient, something your own body makes that declines with age and can apparently be supplemented to reverse that decline. The biohacking crowd has latched onto it hard. And honestly? The underlying science is more interesting than most of what gets passed around on health Twitter.

But here's the problem. Ask ten people about their MOTS-c protocol and you'll get ten completely different answers. Doses ranging from 5 mg to 50 mg. Injection schedules that make no sense. People cycling it, stacking it, front-loading it. The signal-to-noise ratio is terrible, because the research is still early and the internet fills in the gaps with guesswork.

This guide cuts through that. Below you'll find a clear MOTS-c dosage chart, a week-by-week titration approach, what the actual evidence supports, and who this peptide is genuinely right for — and who it isn't. If you've been searching for a dosage protocol that doesn't read like it was written by a supplement company, you're in the right place.

What Is MOTS-C, Really?

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-C) is a peptide encoded not by your nuclear DNA, but by your mitochondrial genome — the small, separate loop of DNA sitting inside your mitochondria. That's unusual. Almost everything your cells make is directed by nuclear DNA. MOTS-c is one of a class of molecules called mitochondrial-derived peptides (MDPs), and it was only formally identified in 2015 by researchers at the University of Southern California.

Think of your mitochondria as power plants that also double as command centers. MOTS-c is one of the signals those command centers send out to the rest of the cell when energy status changes. It travels from the mitochondria to the cell nucleus, where it regulates genes involved in metabolism and stress response. It also enters the bloodstream and acts systemically, which is what makes it interesting as a therapeutic target.

Here's the kicker: MOTS-c levels decline with age. Older adults have measurably lower circulating MOTS-c than younger adults. And in cohort studies of centenarians, certain genetic variants associated with higher MOTS-c activity are overrepresented. Whether that's causal or correlational is still being worked out. But the direction of the association is consistent enough that researchers are paying serious attention.

How MOTS-C Works: The Mechanism in Plain English

MOTS-c works primarily through two pathways you've probably heard of: AMPK (AMP-activated protein kinase) and the folate cycle.

AMPK is essentially your cell's fuel gauge. When energy is low, AMPK switches on pathways that generate more ATP (your cell's currency for energy) and switches off pathways that burn energy unnecessarily. Activating AMPK is also what metformin and fasting do — it's a well-validated metabolic target. MOTS-c activates AMPK directly, which triggers glucose uptake into muscle cells, improves insulin sensitivity, and shifts cells toward fat oxidation.

The folate cycle connection is more nuanced. MOTS-c appears to inhibit an enzyme called DHFR (dihydrofolate reductase), which disrupts the one-carbon pathway used for nucleotide synthesis and methylation. That disruption activates AMPK as a downstream response. It's a mechanistic chain: MOTS-c inhibits DHFR, DHFR inhibition activates AMPK, AMPK activation improves metabolic flexibility. Elegant, but also a reminder that this molecule touches multiple systems simultaneously.

Here's the catch: most of what we know about these mechanisms comes from cell studies and mouse models. The human data, while promising, is limited. You are not a mouse. The dose that does something useful in a rodent doesn't translate linearly to humans, and the long-term effects of exogenous MOTS-c administration in people remain largely unknown.

What the Evidence Actually Shows

Let's be specific about what's been studied, and what population it was studied in.

• Insulin sensitivity and glucose metabolism: In a 2021 randomized controlled trial of 12 older adults with overweight or obesity, a single intravenous dose of MOTS-c at 2 mg/kg improved insulin-stimulated glucose disposal by approximately 15% compared to placebo, measured by hyperinsulinemic-euglycemic clamp. This is the most rigorous human evidence we have. One study, small sample, acute dosing — but it's real human data.
• Exercise performance and fat oxidation: In mouse studies, MOTS-c improved treadmill endurance and increased fat oxidation during exercise. Separately, a 2019 study found that MOTS-c levels rise naturally during intense exercise in humans, suggesting it functions as an exercise-mimetic signal. Whether supplementing it amplifies this response in humans hasn't been formally tested.
• Aging and inflammation: Preclinical data in aged mice shows MOTS-c reducing markers of metabolic syndrome and extending healthspan metrics. In vitro (cell) work shows anti-inflammatory effects via NF-kB suppression. Promising, but still preclinical.
• Weight and body composition: High-fat-diet mice given MOTS-c gained significantly less weight and maintained better glucose tolerance than controls. The mechanism appears to be both increased energy expenditure and reduced lipogenesis. Human body composition trials don't exist yet.

The honest summary: the mechanism is well-supported, the mouse data is compelling, and there's one solid human metabolic study. That's a better evidence base than most peptides you'll find being sold online, but it's nowhere near the bar we'd want for a standard-of-care recommendation.

MOTS-C Dosage Chart: A Week-by-Week Titration Protocol

The most commonly referenced dosing in clinical and research contexts runs between 5 mg and 10 mg per injection, administered subcutaneously (under the skin), typically 3 to 5 times per week. The single human RCT used intravenous dosing (2 mg/kg), which doesn't map cleanly to subcutaneous self-administration. What follows is a conservative titration framework based on available research, clinical reasoning, and reported protocols — not a prescription.

Timing: When to Inject for Best Results

Most protocols recommend injecting MOTS-c in the morning, ideally 30 to 60 minutes before exercise. The rationale: MOTS-c appears to act as an exercise-mimetic signal, so timing it with actual exercise may produce an additive effect on AMPK activation and fat oxidation. If you're not training that day, morning injection before food is the next-best option.

Cycling: Should You Take Breaks?

Standard peptide cycling logic suggests an 8-to-12-week on-cycle followed by a 4-to-6-week break. The rationale is receptor sensitivity — though whether MOTS-c actually causes receptor downregulation with continuous use is not yet established in humans. Cycling is a precautionary approach, not a proven necessity.

MOTS-C and Exercise: Stack Timing

If you're using MOTS-c specifically for performance or metabolic health, pairing it with an exercise protocol that includes zone 2 cardio and resistance training makes mechanistic sense. MOTS-c activates the same AMPK pathway that endurance exercise activates. The combination isn't just additive in theory — it's the physiological context in which MOTS-c naturally operates. Pair it with a quality protein source post-training to support muscle protein synthesis. Healthspan's Alpha-Lactalbumin Protein is worth considering here — alpha-lactalbumin has a high essential amino acid profile and supports muscle repair in a way that complements a metabolically-focused protocol.

The Reality Check: What We Don't Know

The internet wants MOTS-c to be an exercise pill that also reverses metabolic aging. The research is more nuanced — and frankly, more interesting — than that framing.

We don't know the optimal dose for humans. The one human RCT used IV administration, which has completely different pharmacokinetics than subcutaneous injection. We don't know the ideal cycle length, whether continuous use causes desensitization, or what the long-term safety profile looks like. We don't have trials powered to detect effects on body composition, VO2 max, or insulin resistance over months.

What we do know: the mechanism is real, the acute human metabolic data is positive, and the age-decline pattern is consistent with the hypothesis that restoring MOTS-c levels could be beneficial. That's enough to make it worth serious clinical attention. It's not enough to walk into it without biomarker monitoring and a clinician in your corner.

One more thing: peptide quality matters enormously. Unlike pharmaceutical drugs, peptides sold outside a compounding pharmacy have no regulatory quality oversight. Purity, concentration accuracy, and sterility vary wildly. This is not a theoretical concern — it's the main risk vector for anyone trying to source these compounds independently.

Who Is MOTS-C Actually Right For?

Be honest with yourself here. MOTS-c is not a beginner's protocol. It's worth considering if you're:

• Over 40, with declining metabolic flexibility — your fasting glucose is trending up, you're gaining fat more easily despite not changing your diet or training, your energy during exercise has dropped.
• Metabolically compromised — insulin resistance, prediabetes, or elevated HbA1c despite lifestyle interventions. The human trial specifically enrolled this population.
Serious about performance — not casual fitness, but someone who is tracking VO2 max, training consistently, and has plateaued on standard interventions.
• Already doing the basics — sleep optimized, diet dialed in, training consistently. MOTS-c is not a substitute for those foundations.

You're probably not the right candidate if you're looking for a shortcut, if you've never worked with an injectable peptide before and have no clinical support, or if your metabolic labs are completely normal. There's no evidence of benefit in metabolically healthy young adults, and no reason to introduce an experimental peptide without a clinical rationale.

Risks and Side Effects

MOTS-c has a relatively short track record in humans, so the safety profile is still being established. What's known or reasonably anticipated:

• Injection site reactions: Redness, mild swelling, or irritation at the injection site. Usually transient and manageable with proper rotation of sites.
• Hypoglycemia risk: Because MOTS-c improves insulin sensitivity and glucose uptake, combining it with other glucose-lowering agents (metformin, SGLT2 inhibitors, GLP-1 agonists) could theoretically push glucose too low. This needs clinical monitoring.
• Unknown long-term effects: No multi-year human safety data exists. This is the biggest honest caveat.
• Contamination risk from unregulated sources: As noted above, non-pharmaceutical-grade peptides carry real risks of impurity or inaccurate dosing.
• Theoretical immune modulation: MOTS-c has anti-inflammatory effects. Whether this becomes clinically relevant with chronic use is unknown.

Clinical supervision isn't just a nice-to-have here. It's what converts this from an experiment into a monitored protocol with actual safety guardrails.

How to Get Started with MOTS-C at Healthspan

Ready for some practical information that won't leave you searching Reddit for answers? Healthspan's approach to MOTS-c starts with biomarker context, not a generic dose. The Longevity Pro Panel gives you the metabolic baseline you need before starting any peptide protocol — fasting glucose, insulin, HbA1c, inflammatory markers, and more. You can't titrate intelligently without knowing where you're starting.

From there, Healthspan's clinicians work with you to determine whether MOTS-c is appropriate for your specific profile, what starting dose makes sense given your labs and goals, and how to monitor progress. The protocol includes compounded MOTS-c from a licensed pharmacy, meaning quality and concentration are verified — not a grey-market gamble. Follow-up labs and dose adjustments are built into the process, not bolted on as an afterthought.

If your goals are primarily metabolic — glucose regulation, weight, insulin sensitivity — Healthspan's AMPK Blend targets the same AMPK pathway through well-characterized compounds and can be run alongside or instead of MOTS-c depending on where you are on the evidence-comfort spectrum. The Cellular Renewal Stack and Mitophagy Formula round out a mitochondrial health approach if you're looking at the bigger picture. For ongoing glucose tracking, the CGM Metabolic Protocol gives you real-time visibility into how your body responds to the protocol — arguably the most useful feedback loop available.

Schedule a consultation with a Healthspan clinician to find out whether a MOTS-c protocol belongs in your longevity stack.

Frequently Asked Questions About MOTS-C Dosage

What is the standard MOTS-c dosage for humans?

The most commonly referenced subcutaneous doses in clinical contexts range from 5 mg to 10 mg per injection, administered 3 to 5 times per week. The only published human RCT used an intravenous dose of 2 mg/kg, which doesn't translate directly to subcutaneous dosing. Starting at 2.5 to 5 mg three times per week and titrating up is the conservative approach most clinicians recommend.

How often should you inject MOTS-c?

Most protocols use 3 to 5 injections per week, not daily dosing. Starting at 3 times per week allows you to assess tolerance and response before increasing frequency. Some protocols run 5 days on, 2 days off to mirror a training week and provide periodic recovery from the injection schedule.

When is the best time to take MOTS-c?

Morning, ideally 30 to 60 minutes before exercise, is the most commonly recommended timing. MOTS-c activates AMPK — the same pathway triggered by endurance exercise — so pairing the injection with a workout may produce an additive effect on fat oxidation and metabolic signaling. On rest days, morning injection before food is the alternative.

How long does a MOTS-c cycle last?

Standard protocols run 8 to 12 weeks on, followed by a 4 to 6 week break. This cycling approach is based on general peptide pharmacology and precautionary reasoning about receptor sensitivity, though whether MOTS-c specifically requires cycling hasn't been confirmed in human research. Most experienced clinicians recommend cycling as a conservative default.

Can you stack MOTS-c with other metabolic compounds?

Yes, but with caution. MOTS-c works through the AMPK pathway, which overlaps mechanistically with metformin, berberine, and SGLT2 inhibitors. Stacking multiple AMPK activators can theoretically push glucose too low, especially in people with existing insulin sensitivity or those on glucose-lowering medications. Always review stacks with a clinician before combining, and monitor fasting glucose and HbA1c during the protocol.

Does MOTS-c help with weight loss?

In mouse studies, MOTS-c prevented obesity on a high-fat diet and increased fat oxidation. Human weight loss trials don't exist yet. The metabolic mechanisms — AMPK activation, improved insulin sensitivity, increased glucose uptake into muscle — are consistent with weight management benefits, but extrapolating mouse data to human fat loss outcomes requires significant caution.

What labs should you check before starting MOTS-c?

At minimum: fasting glucose, fasting insulin, HbA1c, a comprehensive metabolic panel, and ideally inflammatory markers like hsCRP. These give you a metabolic baseline to measure against and help identify whether you have the kind of metabolic dysfunction that MOTS-c's evidence base most directly addresses. Repeat the same panel at 8 to 12 weeks to assess response.